Discover Pharma

Ariadne Bio has launched with funding from The Michael J Fox Foundation to advance AB-300, an investigational treatment for apathy associated with Parkinson's disease. Drug targets apathy in Parkinson's disease Ariadne Bio has been spun out by Palomar Lab

MaaT Pharma plans to advance a global Phase 3 trial of MaaT013 after European regulators maintained a negative opinion on its marketing application. EMA calls for more evidence on MaaT013 The Committee for Medicinal Products for Human Use (CHMP) of the Eu

Saudi Arabia has announced more than SAR 5 billion in biotechnology agreements and initiatives as it expands investment in research, manufacturing, clinical trials and talent. Saudi Arabia expands biotechnology infrastructure More than 40 agreements, init

Big Picture Bio has launched with £2.2 million in funding to develop AI-designed drug combinations for cancer and immune-mediated diseases.AI platform targets cancer drug combinationsThe UK biotech has closed a £1.5 million pre-seed funding round co-led b

Skyhawk Therapeutics' investigational oral treatment SKY-0515 showed a 1.59-point difference in disease progression at 15 months versus an external natural-history control in a Phase 1/2 Huntington's disease study. Clinical measures favoured SKY-0515 At t

Oncodesign Services and Nexus BioQuest have formed a preclinical research partnership combining human-relevant in vitro models with in vivo pharmacology expertise for biotech drug development programmes. Partnership combines in vitro and in vivo models Th

Nabsys' Electronic Genome Mapping technology detected clinically relevant genomic abnormalities across five samples of acute and chronic myeloid leukaemia in a proof-of-principle study from Augusta University. EGM matched standard cytogenetic findings The

Calibre Health Labs has secured CQC registration, allowing its doctors to provide clinical care directly to members as the company expands its AI-powered health service across the UK. CQC registration enables nationwide expansion The registration means Ca

Cyllene Therapeutics' experimental gene therapy EG110A has received US FDA Regenerative Medicine Advanced Therapy (RMAT) designation for neurogenic detrusor overactivity (NDO), a bladder disorder that can cause severe urinary incontinence. The designation

Contactless monitoring of nocturnal cough has been linked to worsening asthma symptoms for up to three days, suggesting a potential objective measure of disease activity. Study captures cough without patient intervention New data from Leiden University Me